Marisel Rosell-Díaz , Anna Petit-Gay , Clàudia Molas-Prat , Laura Gallardo-Nuell , Lluís Ramió-Torrentà , Josep Garre-Olmo , Vicente Pérez-Brocal , Andrés Moya , Mariona Jové , Reinald Pamplona , Josep Puig , Rafael Ramos , Fredrik Bäckhed , Jordi Mayneris-Perxachs , José Manuel Fernández-Real
{"title":"二甲双胍诱导的肠道微生物组和血浆代谢组变化与男性认知能力有关。","authors":"Marisel Rosell-Díaz , Anna Petit-Gay , Clàudia Molas-Prat , Laura Gallardo-Nuell , Lluís Ramió-Torrentà , Josep Garre-Olmo , Vicente Pérez-Brocal , Andrés Moya , Mariona Jové , Reinald Pamplona , Josep Puig , Rafael Ramos , Fredrik Bäckhed , Jordi Mayneris-Perxachs , José Manuel Fernández-Real","doi":"10.1016/j.metabol.2024.155941","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>An altered gut microbiome characterized by reduced abundance of butyrate producing bacteria and reduced gene richness is associated with type 2 diabetes (T2D). An important complication of T2D is increased risk of cognitive impairment and dementia. The biguanide metformin is a commonly prescribed medication for the control of T2D and metformin treatment has been associated with a significant reduction in the risk of dementia and improved cognition, particularly in people with T2D.</p></div><div><h3>Aim</h3><p>To investigate the associations of metformin use with cognition exploring potential mechanisms by analyzing the gut microbiome and plasma metabolome using shotgun metagenomics and HPLC-ESI-MS/MS, respectively.</p></div><div><h3>Methods</h3><p>We explored two independent cohorts: an observational study (Aging Imageomics) and a phase IV, randomized, double-blind, parallel-group, randomized pilot study (MEIFLO). From the two studies, we analyzed four study groups: (1) individuals with no documented medical history or medical treatment (<em>n</em> = 172); (2) people with long-term T2D on metformin monotherapy (<em>n</em> = 134); (3) people with long-term T2D treated with oral hypoglycemic agents other than metformin (<em>n</em> = 45); (4) a newly diagnosed T2D subjects on metformin monotherapy (<em>n</em> = 22). Analyses were also performed stratifying by sex.</p></div><div><h3>Results</h3><p>Several bacterial species belonging to the Proteobacteria (<em>Escherichia coli</em>) and Verrucomicrobia (<em>Akkermansia muciniphila</em>) phyla were positively associated with metformin treatment, while bacterial species belonging to the Firmicutes phylum (<em>Romboutsia timonensis</em>, <em>Romboutsia ilealis</em>) were negatively associated. Due to the consistent increase in <em>A. muciniphila</em> and decrease in <em>R.ilealis</em> in people with T2D subjects treated with metformin, we investigated the association between this ratio and cognition. In the entire cohort of metformin-treated T2D subjects, the <em>A.muciniphila</em>/<em>R.ilealis</em> ratio was not significantly associated with cognitive test scores. However, after stratifying by sex, the <em>A.muciniphila</em>/<em>R. ilealis</em> ratio was significantly and positively associated with higher memory scores and improved memory in men.</p><p>Metformin treatment was associated with an enrichment of microbial pathways involved in the TCA cycle, and butanoate, arginine, and proline metabolism in both cohorts. The bacterial genes involved in arginine metabolism, especially in production of glutamate (<em>astA, astB, astC, astD, astE, putA</em>), were enriched following metformin intake. In agreement, in the metabolomics analysis, metformin treatment was strongly associated with the amino acid proline, a metabolite involved in the metabolism of glutamate.</p></div><div><h3>Conclusions</h3><p>The beneficial effects of metformin may be mediated by changes in the composition of the gut microbiota and microbial-host-derived co-metabolites.</p></div>","PeriodicalId":18694,"journal":{"name":"Metabolism: clinical and experimental","volume":"157 ","pages":"Article 155941"},"PeriodicalIF":10.8000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0026049524001689/pdfft?md5=0306d82cc1c5aa62af161906acde9ece&pid=1-s2.0-S0026049524001689-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men\",\"authors\":\"Marisel Rosell-Díaz , Anna Petit-Gay , Clàudia Molas-Prat , Laura Gallardo-Nuell , Lluís Ramió-Torrentà , Josep Garre-Olmo , Vicente Pérez-Brocal , Andrés Moya , Mariona Jové , Reinald Pamplona , Josep Puig , Rafael Ramos , Fredrik Bäckhed , Jordi Mayneris-Perxachs , José Manuel Fernández-Real\",\"doi\":\"10.1016/j.metabol.2024.155941\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>An altered gut microbiome characterized by reduced abundance of butyrate producing bacteria and reduced gene richness is associated with type 2 diabetes (T2D). An important complication of T2D is increased risk of cognitive impairment and dementia. The biguanide metformin is a commonly prescribed medication for the control of T2D and metformin treatment has been associated with a significant reduction in the risk of dementia and improved cognition, particularly in people with T2D.</p></div><div><h3>Aim</h3><p>To investigate the associations of metformin use with cognition exploring potential mechanisms by analyzing the gut microbiome and plasma metabolome using shotgun metagenomics and HPLC-ESI-MS/MS, respectively.</p></div><div><h3>Methods</h3><p>We explored two independent cohorts: an observational study (Aging Imageomics) and a phase IV, randomized, double-blind, parallel-group, randomized pilot study (MEIFLO). From the two studies, we analyzed four study groups: (1) individuals with no documented medical history or medical treatment (<em>n</em> = 172); (2) people with long-term T2D on metformin monotherapy (<em>n</em> = 134); (3) people with long-term T2D treated with oral hypoglycemic agents other than metformin (<em>n</em> = 45); (4) a newly diagnosed T2D subjects on metformin monotherapy (<em>n</em> = 22). Analyses were also performed stratifying by sex.</p></div><div><h3>Results</h3><p>Several bacterial species belonging to the Proteobacteria (<em>Escherichia coli</em>) and Verrucomicrobia (<em>Akkermansia muciniphila</em>) phyla were positively associated with metformin treatment, while bacterial species belonging to the Firmicutes phylum (<em>Romboutsia timonensis</em>, <em>Romboutsia ilealis</em>) were negatively associated. Due to the consistent increase in <em>A. muciniphila</em> and decrease in <em>R.ilealis</em> in people with T2D subjects treated with metformin, we investigated the association between this ratio and cognition. In the entire cohort of metformin-treated T2D subjects, the <em>A.muciniphila</em>/<em>R.ilealis</em> ratio was not significantly associated with cognitive test scores. However, after stratifying by sex, the <em>A.muciniphila</em>/<em>R. ilealis</em> ratio was significantly and positively associated with higher memory scores and improved memory in men.</p><p>Metformin treatment was associated with an enrichment of microbial pathways involved in the TCA cycle, and butanoate, arginine, and proline metabolism in both cohorts. The bacterial genes involved in arginine metabolism, especially in production of glutamate (<em>astA, astB, astC, astD, astE, putA</em>), were enriched following metformin intake. In agreement, in the metabolomics analysis, metformin treatment was strongly associated with the amino acid proline, a metabolite involved in the metabolism of glutamate.</p></div><div><h3>Conclusions</h3><p>The beneficial effects of metformin may be mediated by changes in the composition of the gut microbiota and microbial-host-derived co-metabolites.</p></div>\",\"PeriodicalId\":18694,\"journal\":{\"name\":\"Metabolism: clinical and experimental\",\"volume\":\"157 \",\"pages\":\"Article 155941\"},\"PeriodicalIF\":10.8000,\"publicationDate\":\"2024-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0026049524001689/pdfft?md5=0306d82cc1c5aa62af161906acde9ece&pid=1-s2.0-S0026049524001689-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Metabolism: clinical and experimental\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0026049524001689\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolism: clinical and experimental","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0026049524001689","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men
Background
An altered gut microbiome characterized by reduced abundance of butyrate producing bacteria and reduced gene richness is associated with type 2 diabetes (T2D). An important complication of T2D is increased risk of cognitive impairment and dementia. The biguanide metformin is a commonly prescribed medication for the control of T2D and metformin treatment has been associated with a significant reduction in the risk of dementia and improved cognition, particularly in people with T2D.
Aim
To investigate the associations of metformin use with cognition exploring potential mechanisms by analyzing the gut microbiome and plasma metabolome using shotgun metagenomics and HPLC-ESI-MS/MS, respectively.
Methods
We explored two independent cohorts: an observational study (Aging Imageomics) and a phase IV, randomized, double-blind, parallel-group, randomized pilot study (MEIFLO). From the two studies, we analyzed four study groups: (1) individuals with no documented medical history or medical treatment (n = 172); (2) people with long-term T2D on metformin monotherapy (n = 134); (3) people with long-term T2D treated with oral hypoglycemic agents other than metformin (n = 45); (4) a newly diagnosed T2D subjects on metformin monotherapy (n = 22). Analyses were also performed stratifying by sex.
Results
Several bacterial species belonging to the Proteobacteria (Escherichia coli) and Verrucomicrobia (Akkermansia muciniphila) phyla were positively associated with metformin treatment, while bacterial species belonging to the Firmicutes phylum (Romboutsia timonensis, Romboutsia ilealis) were negatively associated. Due to the consistent increase in A. muciniphila and decrease in R.ilealis in people with T2D subjects treated with metformin, we investigated the association between this ratio and cognition. In the entire cohort of metformin-treated T2D subjects, the A.muciniphila/R.ilealis ratio was not significantly associated with cognitive test scores. However, after stratifying by sex, the A.muciniphila/R. ilealis ratio was significantly and positively associated with higher memory scores and improved memory in men.
Metformin treatment was associated with an enrichment of microbial pathways involved in the TCA cycle, and butanoate, arginine, and proline metabolism in both cohorts. The bacterial genes involved in arginine metabolism, especially in production of glutamate (astA, astB, astC, astD, astE, putA), were enriched following metformin intake. In agreement, in the metabolomics analysis, metformin treatment was strongly associated with the amino acid proline, a metabolite involved in the metabolism of glutamate.
Conclusions
The beneficial effects of metformin may be mediated by changes in the composition of the gut microbiota and microbial-host-derived co-metabolites.
期刊介绍:
Metabolism upholds research excellence by disseminating high-quality original research, reviews, editorials, and commentaries covering all facets of human metabolism.
Consideration for publication in Metabolism extends to studies in humans, animal, and cellular models, with a particular emphasis on work demonstrating strong translational potential.
The journal addresses a range of topics, including:
- Energy Expenditure and Obesity
- Metabolic Syndrome, Prediabetes, and Diabetes
- Nutrition, Exercise, and the Environment
- Genetics and Genomics, Proteomics, and Metabolomics
- Carbohydrate, Lipid, and Protein Metabolism
- Endocrinology and Hypertension
- Mineral and Bone Metabolism
- Cardiovascular Diseases and Malignancies
- Inflammation in metabolism and immunometabolism